The US Food and Drug Administration (FDA) has cleared a health claim petition for chromium picolinate, a supplement that has been shown to reduce the risk of insulin resistance and type 2 diabetes.
Researchers are expecting several conclusive peer-reviewed studies to be published in the months ahead that should help build evidence to support additional health claims for chromium picolinate.
Insulin resistance is an epidemic condition that dramatically increases risk for type 2 diabetes, coronary heart disease and stroke. According to the Canadian Diabetes Association, more than two million Canadians have diabetes, approximately 90% of these people have type 2 diabetes.
Chromium is used to make glucose tolerance factor, a compound that interacts with insulin and helps maintain normal blood-sugar levels. With adequate amounts of chromium present, the body uses less insulin to do its job. Some studies have shown that chromium is lost from the body at an increased rate with aging and in the presence if type 2 diabetes.
Supplements made from chromium picinolate are thought to be absorbed more efficiently than those made from chromium chloride or chromium nictinate.
All research on this web site is the property of Leslie Beck Nutrition Consulting Inc. and is protected by copyright. Keep in mind that research on these matters continues daily and is subject to change. The information presented is not intended as a substitute for medical treatment. It is intended to provide ongoing support of your healthy lifestyle practices.